



ZBP1 promotes fungi-induced inflammasome activation and pyroptosis, apoptosis, and necroptosis (PANoptosis)

Received for publication, September 4, 2020, and in revised form, October 8, 2020. Published, Papers in Press, October 27, 2020. DOI 10.1074/jbc.RA120.015924

Balaji Banoth[‡], Shraddha Tuladhar[‡], Rajendra Karki, Bhesh Raj Sharma, Benoit Briard, Sannula Kesavardhana, Amanda Burton, and Thirumala-Devi Kanneganti*

From the Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA

Edited by Ursula Jakob

Candida albicans and *Aspergillus fumigatus* are dangerous fungal pathogens with high morbidity and mortality, particularly in immunocompromised patients. Innate immune-mediated programmed cell death (pyroptosis, apoptosis, necroptosis) is an integral part of host defense against pathogens. Inflammasomes, which are canonically formed upstream of pyroptosis, have been characterized as key mediators of fungal sensing and drivers of proinflammatory responses. However, the specific cell death pathways and key upstream sensors activated in the context of *Candida* and *Aspergillus* infections are unknown. Here, we report that *C. albicans* and *A. fumigatus* infection induced inflammatory programmed cell death in the form of pyroptosis, apoptosis, and necroptosis (PANoptosis). Further, we identified the innate immune sensor Z-DNA binding protein 1 (ZBP1) as the apical sensor of fungal infection responsible for activating the inflammasome/pyroptosis, apoptosis, and necroptosis. The Z α 2 domain of ZBP1 was required to promote this inflammasome activation and PANoptosis. Overall, our results demonstrate that *C. albicans* and *A. fumigatus* induce PANoptosis and that ZBP1 plays a vital role in inflammasome activation and PANoptosis in response to fungal pathogens.

Mycotic diseases pose a significant global health burden, particularly among immunocompromised patients, and they are under studied compared with other infectious diseases (1). *Candida albicans* and *Aspergillus fumigatus* infections often result in invasive candidiasis and aspergilliosis if not cleared early, and they are among the most dangerous fungal pathogens with high morbidity and mortality rates (2, 3). The host innate immune system is critical for recognizing fungal particles and mediating their clearance (4). Innate immune-mediated programmed cell death (pyroptosis, apoptosis, necroptosis) is also an essential part of this host defense (5). Pathogen-associated molecular patterns and damage-associated molecular patterns (PAMPs and DAMPs) are recognized through pattern recognition receptors (PRRs) and can cause the formation of cytosolic multimeric protein complexes known as inflammasomes (6). The inflammasome drives the activation of the inflammatory caspase-1 (CASP1), which further proteolytically processes cytokines including interleukin (IL)-1 β and IL-18 and the executioner molecule gasdermin D (GSDMD), resulting in pyroptotic cell death (6–8). Previously, we have characterized inflam-

masome sensors, including NLRP3 and AIM2, to mediate innate immune responses against fungal pathogens, *C. albicans* and *A. fumigatus* (9–11). Fungi-mediated inflammasome activation causes cytokine release and tissue damage because of inflammatory cell death (12). In addition to pyroptosis, other forms of programmed cell death important for host defense include apoptosis and necroptosis. Apoptosis is induced on activation of apical caspases caspase-8 (CASP8) or caspase-9 (CASP9) that results in activation of executioner caspases, including caspase-3 (CASP3) and caspase-7 (CASP7) (13, 14). The apoptotic caspase-3 can also activate gasdermin E to induce a lytic form of cell death (15). During necroptosis, proteins containing a receptor interacting protein (RIP) homotypic interaction motif (RHIM), including RIP kinase 1 (RIPK1) and RIP kinase 3 (RIPK3), play crucial roles in the phosphorylation of the mixed lineage kinase domain-like pseudokinase (MLKL), which executes cell death (13, 16).

The identification of extensive cross-talk between pyroptosis, apoptosis, and necroptosis has led to the establishment of the concept of “PANoptosis” (17–30). PANoptosis ('P', Pyroptosis; 'A', Apoptosis; 'N', Necroptosis; and 'optosis', a form of programmed cell death) is defined as “a unique inflammatory programmed cell death regulated by the PANoptosome, which provides a molecular scaffold that allows for interactions and activation of the machinery required for inflammasome/pyroptosis (such as NLRP3, ASC, caspase-1), apoptosis (caspase-8), and necroptosis (RIPK3/RIPK1)” (17, 25, 28, 29). The ability of these molecules to interact allows for intricate coregulation between cell death pathways that had previously been thought to be independent. PANoptosis has been implicated in infectious and autoinflammatory diseases, cancer, and beyond (17–21, 23, 25, 26, 29, 30), and the molecular details and phenotypic outcomes of the cross-talk and coregulation among pyroptosis, apoptosis, and necroptosis are dependent on the stimulus provided.

In this study, we show that *C. albicans* and *A. fumigatus* infection elicited inflammasome activation and pyroptosis, apoptosis, and necroptosis (PANoptosis). We found that the innate immune sensor Z-DNA binding protein 1 (ZBP1) functioned as the apical sensor to activate the *C. albicans* and *A. fumigatus*-induced inflammasome/pyroptosis, apoptosis, and necroptosis. Further, we demonstrate that the nucleic acid binding domain Z α 2 of ZBP1 is crucial for *C. albicans*- and *A. fumigatus*-induced inflammasome activation and PANoptotic cell death. Collectively, our results establish that *C. albicans*

[‡]These authors contributed equally to this work.

*For correspondence: Thirumala-Devi Kanneganti, Thirumala-Devi.Kanneganti@StJude.org.




Figure 1. PANoptosis in response to *C. albicans*. A–C, Western blotting analysis of PANoptosis activation markers in bone marrow-derived macrophages (BMDMs) after *C. albicans* infection. A, Pyroptosis activation is assessed by immunoblotting of cleaved caspase-1 (CASP1) (p20) and gasdermin D (GSDMD) (p30). B, Apoptosis activation is determined by immunoblotting of active initiator CASP8 (p18) and executioner caspases CASP3 (p19/17) and CASP7 (p20). C, Necroptosis activation is indicated by the phosphorylation of mixed lineage kinase domain-like pseudokinase (pMLKL). Total MLKL (tMLKL) and GAPDH are used as loading controls. Molecular weight marker sizes are indicated on the right (kDa). D, Quantification of cell death in primary human peripheral blood mononuclear cells (hPBMCs) following *C. albicans* infection. Data presented are representative of three independent experiments. 2-way ANOVA was used to determine statistical significance. *** $P < 0.001$ moi, multiplicity of infection; UT, untreated. Black asterisks denote a nonspecific band.

and *A. fumigatus* induce PANoptosis and that ZBP1 is critical for inflammasome activation and PANoptosis in response to fungal pathogens.

Results

C. albicans and *A. fumigatus* infections activate PANoptosis

Our previous studies characterized inflammasomes as key players in sensing fungal infection and activating proinflammatory responses (9, 10), but the specific cell death pathways activated in response to *C. albicans* and *A. fumigatus* remain unknown. Therefore, we systematically analyzed the programmed cell death pathways activated by *C. albicans* and *A. fumigatus*. We infected WT BMDMs with varying doses of *C. albicans* and *A. fumigatus* and biochemically assessed markers associated with pyroptosis, apoptosis, and necroptosis (PANoptosis). Consistent with previous reports (10), we found *C. albicans* and *A. fumigatus* elicited inflammasome activation and pyroptosis in a dose-dependent manner, as indicated by activation of CASP1 and GSDMD (Fig. 1A, Fig. S1). Further, characterization of cell death markers associated with apoptosis revealed increased activation of the apoptotic initiator CASP8 (p18) and executioners CASP3 (p17/19) and CASP7 (p20) in a dose-dependent manner (Fig. 1B, Fig. S1). The phosphorylated form of MLKL (pMLKL) is a marker of necroptosis

activation (31). We observed that infection of WT BMDMs resulted in dose-dependent necroptotic cell death as evidenced by the enhanced levels of pMLKL (Fig. 1C, Fig. S1). Further, we also observed a dose-dependent induction of cell death in response to *C. albicans* infection in primary human peripheral blood mononuclear cells (hPBMCs), corroborating our findings in primary BMDMs (Fig. 1D). Overall, these data indicate that fungal infection with *C. albicans* and *A. fumigatus* activates PANoptosis.

Loss of PANoptotic components confers protection against fungi-induced cell death

Because we observed PANoptosis during fungal infection, we further evaluated the role of key molecular components of PANoptosis using a genetic approach. We infected murine BMDMs lacking crucial components of PANoptosis with *C. albicans* or *A. fumigatus* (Fig. 2, Fig. S2). Infection of WT BMDMs with *C. albicans* or *A. fumigatus* resulted in robust activation of proteins involved in pyroptosis, apoptosis, and necroptosis (Fig. 2A–C, Fig. S2A), as observed earlier (Fig. 1). Pyroptotic cell death is largely mediated by CASP1, CASP11, ASC, and GSDMD. Loss of these individual molecules led to reduced activation of pyroptotic proteins (CASP1 and GSDMD; Fig. 2A, Fig. S2A) and had minimal effect on the




Figure 2. Ablation of PANoptotic components inhibits *C. albicans*-induced PANoptosis and inflammation. A–C, Western blotting analysis of PANoptosis activation markers after *C. albicans* infection in the indicated bone marrow-derived macrophages (BMDMs). A, Pyroptosis activation is assessed by immunoblotting of cleaved caspase-1 (CASP1) (p20) and gasdermin D (GSDMD) (p30). B, Apoptosis activation is determined by immunoblotting of active initiator CASP8 (p18) and executioner caspases CASP3 (p19/17) and CASP7 (p20). C, Necroptosis activation is indicated by the phosphorylation of mixed lineage kinase domain-like pseudokinase (pMLKL). Total MLKL (tMLKL) and GAPDH are used as loading controls. ASC and RIPK3 proteins were probed to confirm their deletion in ASC and RIPK3-deficient BMDMs, respectively. Molecular weight marker sizes are indicated on the right (kDa). D, Inflammatory cytokine IL-18 release was evaluated in WT (WT) and *Casp1/11^{-/-} Ripk3^{-/-} Casp8^{-/-}* BMDMs following *C. albicans* infection for 20 h. Data shown are representative of at least three independent experiments (A–D). Unpaired *t* test with Welch’s correction was used to determine statistical significance. ****P* < 0.001 (D). UT, untreated. Black asterisks denote a nonspecific band.

activation of apoptotic proteins (CASP8, CASP3, and CASP7; Fig. 2B, Fig. S2A); however, the expression of pMLKL was clearly increased during *C. albicans* infection and trended toward an increase during *A. fumigatus* infection (Fig. 2C, Fig. S2A), suggesting increased activation of necroptosis when pyroptosis is blocked in response to fungal pathogens. Deficiency of necroptotic mediators MLKL or RIPK3 had minor impacts on the activation of pyroptotic and apoptotic markers (Fig. 2A, B, Fig. S2A). CASP8 regulates both canonical and non-canonical NLRP3 inflammasome activation in bacterial and viral infections (17, 32), and it also negatively regulates the necroptotic pathway (14). BMDMs lacking both CASP8 and RIPK3 were largely protected from *C. albicans*- or *A. fumigatus*-induced PANoptosis, as evident by the reduced activation of pyroptotic (CASP1, GSDMD; Fig. 2A, Fig. S2A), apoptotic (CASP3, CASP7; Fig. 2B, Fig. S2A), and necroptotic (pMLKL) biochemical markers (Fig. 2C, Fig. S2A).

BMDMs lacking critical components of PANoptosis (CASP1, CASP11, RIPK3, and CASP8 combined) are protected from bacteria and virus-induced PANoptosis (17). Similar to the *Ripk3^{-/-} Casp8^{-/-}* cells, *Casp1/11^{-/-} Ripk3^{-/-} Casp8^{-/-}* BMDMs showed reduced activation of host cell death markers in response to *C. albicans* or *A. fumigatus* infection (Fig. 2A–C, Fig. S2A). However, although *Ripk3^{-/-} Casp8^{-/-}* cells showed residual levels of GSDMD activation, the activation of GSDMD was completely abolished in *Casp1/11^{-/-} Ripk3^{-/-} Casp8^{-/-}* BMDMs (Fig. 2A, Fig. S2A). Combined with the reduced activation of caspase-3, -7 and MLKL, these findings suggest cells undergo reduced cell death when crucial components of PANoptosis are missing during fungal infection.

Activation of the inflammasome and inflammatory cell death often results in the release of various cytokines, chemokines, and DAMPs which further amplify the inflammatory response and associated pathology (7, 33). We assessed inflammatory

cytokine IL-18 release after *C. albicans* or *A. fumigatus* infection as a measure of inflammasome activation and associated cell death. WT BMDMs released a significant amount of IL-18 after fungal infection, whereas the *Casp1/11^{-/-}Ripk3^{-/-}Casp8^{-/-}* BMDMs released significantly less (Fig. 2D, Fig. S2B). Together, these findings suggest that the components of PANoptosis are crucial in mediating inflammatory cell death and cytokine release during fungal infection.

ZBP1 regulates PANoptosis and inflammation via its Z α 2 domain

The interferon (IFN)-inducible protein ZBP1, also known as DAI (DNA-dependent activator of IFN regulatory factors), is an innate immune sensor that mediates NLRP3 inflammasome activation in response to influenza A virus (IAV) infection (21, 29). ZBP1 contains two N-terminal nucleic acid binding domains (Z α 1 and Z α 2) followed by a RHIM domain responsible for mediating homotypic interactions with cell death signaling proteins RIPK1 and RIPK3 (20, 41). In the context of IAV, ZBP1 sensing of the virus leads to PANoptosome assembly and drives pyroptosis through NLRP3 inflammasome activation, apoptosis via FADD-CASP8, and necroptosis through RIPK3-MLKL (17, 21, 29, 34–37), with CASP6 promoting the association between ZBP1 and RIPK3 (29). However, the role of ZBP1 in inflammasome activation and PANoptosis in response to other pathogens and fungi is not known. To understand the contribution of ZBP1 to PANoptosis during fungal infections, we infected BMDMs from WT and ZBP1-deficient mice with *C. albicans* or *A. fumigatus*. The WT BMDMs showed robust activation of the inflammasome and PANoptosis on infection with *C. albicans* or *A. fumigatus* (Fig. 3A–C, Fig. S3A). BMDMs deficient in ZBP1 (*Zbp1^{-/-}* cells) had reduced activation of the inflammasome and pyroptosis, as shown by the reduced cleavage of CASP1 and GSDMD (Fig. 3A, Fig. S3A). The activation of apoptosis and necroptosis as measured by the cleavage of CASP8, CASP3, and CASP7 and the level of pMLKL were also abrogated in the ZBP1-deficient BMDMs (Fig. 3B, C, Fig. S3A), and the changes in pMLKL were more notable with *C. albicans* than *A. fumigatus*. Thus, our results show a crucial role for the master regulator ZBP1 in controlling fungi-induced inflammasome activation and PANoptosis.

To further understand how ZBP1 mediated the activation of PANoptosis, we examined the role of the Z α 2 domain in this process. Recently, the Z α 2 domain was shown to act as a molecular switch in regulating IAV-induced NLRP3 inflammasome activation and PANoptosis (20). The Z α 2 domain of ZBP1 senses endogenous and IAV-derived nucleic acids to mediate cell death and inflammation (20, 38), but whether it can do the same with fungal ligands is unknown. We infected WT and *Zbp1 Δ Z α 2/ Δ Z α 2* BMDMs with *C. albicans* or *A. fumigatus* and biochemically assessed markers of PANoptosis. Inflammasome activation occurred in WT BMDMs, indicated by CASP1 and GSDMD cleavage, but their levels were substantially reduced in *Zbp1^{-/-}* and *Zbp1 Δ Z α 2/ Δ Z α 2* BMDMs (Fig. 3A, Fig. S3A). These findings suggest that the Z α 2 domain of ZBP1 is essential for inflammasome activation and the induction of pyroptosis in response to fungal pathogens. In addition, both

the *Zbp1^{-/-}* and *Zbp1 Δ Z α 2/ Δ Z α 2* BMDMs showed similarly reduced activation of the markers of apoptosis (CASP8, CASP3, and CASP7) and necroptosis (pMLKL) (Fig. 3B, C, Fig. S3A). Overall, our results suggest that the Z α 2 domain of ZBP1 is critical to trigger PANoptosis during fungal infection.

Given the clear role for ZBP1 in *C. albicans*- or *A. fumigatus*-mediated inflammasome activation and PANoptosis, we assessed the release of the inflammatory cytokine IL-18 after fungal infection. WT BMDMs had increased secretion of IL-18 following infection with *C. albicans* or *A. fumigatus* (Fig. 3D, Fig. S3B), whereas the *Zbp1^{-/-}* and *Zbp1 Δ Z α 2/ Δ Z α 2* BMDMs had significantly reduced IL-18 release compared with the WT (Fig. 3D, Fig. S3B). The IL-18 release data further support that there is dampened inflammasome activation in BMDMs lacking *Zbp1^{-/-}* and *Zbp1 Δ Z α 2/ Δ Z α 2* compared with WT BMDMs. These observations suggest that ZBP1, specifically the Z α 2 domain, plays a crucial role in inducing inflammasome activation and PANoptosis in response to fungal pathogens. These results also suggest that ZBP1 senses fungal pathogens, including *C. albicans* and *A. fumigatus*, and may form a PANoptosome complex similar to that observed during bacterial and viral infections along with RIPK1, RIPK3, CASP8, CASP1, and FADD to induce PANoptosis (Fig. 3E).

Discussion

In the current study, we demonstrate that the fungal pathogens *C. albicans* and *A. fumigatus* activate the ZBP1-PANoptosome, driving inflammasome activation and PANoptosis. The loss of the PANoptosome component ZBP1 or associated molecules led to inhibition of inflammasome activation, PANoptosis, and inflammatory cytokine release, and the ZBP1-Z α 2 domain was crucial for these processes. PANoptosis plays a major role in host defense against pathogenic infections in addition to its functions in development and inflammatory pathophysiology (17, 19–28). Thus far, ZBP1- and TAK1-regulated PANoptosome complexes have been identified to mediate PANoptosis (17, 25, 27–29). The dynamic composition of these PANoptosome complexes under different pathological conditions remains an active area of research.

Our study is the first to shed light on the role of ZBP1 in inflammasome activation and PANoptosis during fungal infection, and there are several interesting questions that remain to be addressed. One major question is what fungal ligands are sensed by ZBP1. Canonically, ZBP1 is known to trigger innate immune responses through the recognition of nucleic acids from viral pathogens. Fungal pathogens can liberate a variety of PAMPs including nucleic acids that could potentially serve as ligands for ZBP1 (9). It would be interesting to determine whether pure fungal ligands (such as β -glucan, zymosan, mannan) are also capable of triggering PANoptosis.

ZBP1 regulates PANoptosis and inflammasome activation during IAV infection, and genetic ablation of ZBP1 or RIPK3 and CASP8 is sufficient to rescue the host cells from IAV-induced cell death and to block inflammasome activation (20, 21). However, unlike in viral infection, deletion of ZBP1 in our fungal model did not result in a complete loss of CASP1 activation, GSDMD cleavage, or apoptotic protein (CASP8, CASP3,

Fungal Infection Induces PANoptosis




Figure 3: Z α 2 domain of ZBP1 drives PANoptosis. A–C, Western blot analysis of PANoptosis activation markers after *C. albicans* infection in wildtype (WT), *Zbp1*^{-/-}, or *Zbp1*^{ΔZα2/ΔZα2} bone marrow-derived macrophages (BMDMs). A, Pyroptosis activation is assessed by immunoblotting of cleaved caspase-1 (CASP1) (p20) and gasdermin D (GSDMD) (p30). B, Apoptosis activation is determined by immunoblotting of active initiator CASP8 (p18) and executioner caspases CASP3 (p19/17) and CASP7 (p20). C, Necroptosis activation is indicated by the phosphorylation of mixed lineage kinase domain-like pseudokinase (pMLKL). ZBP1 protein was probed to confirm its deletion and MW shift in ZBP1-deficient and *Zbp1*^{ΔZα2/ΔZα2} BMDMs, respectively. Total MLKL (tMLKL) and GAPDH are used as loading controls. Molecular weight marker sizes are indicated on the right (kDa). D, Inflammatory cytokine IL-18 release was evaluated in WT, *Zbp1*^{-/-}, or *Zbp1*^{ΔZα2/ΔZα2} BMDMs following *C. albicans* infection for 20 h. E, Schematic summary of the regulation of PANoptosis by ZBP1 in response to the fungal pathogens *C. albicans* or *A. fumigatus*. ZBP1 senses the fungal pathogen and mediates PANoptosis possibly by engaging the ZBP1-PANoptosome to drive NLRP3-mediated CASP1 activation (pyroptosis), CASP3/CASP7 activation (apoptosis), and MLKL activation (necroptosis). Data shown are representative of at least three independent experiments (A–D). 2-way ANOVA was employed to determine statistical significance. **P* < 0.05 (D). UT, untreated. Red asterisks denote a nonspecific band.

and CASP7) activation. Similarly, RIPK3- and RIPK3/CASP8-deficient BMDMs displayed modest reductions in the activation of pyroptosis. This complex interplay of PANoptosome components during specific infections and inflammatory ailments needs further clarification; there is likely a functional redundancy between molecules involved in the complex, which allows for key functions to be carried out even when a specific protein is lost. Previous findings suggest that it is possible that in the absence of RIPK3, ZBP1 engages the RHIM domain of RIPK1 to recruit FADD/CASP8 and potentiate pyroptosis and apoptosis (25, 26, 39, 40). The residual activation we observed

in ZBP1/RIPK3-deficient BMDMs in this study suggests that there could be additional pathways or PANoptosome components such as RIPK1 that are functioning during fungal infection. In addition to NLRP3, other cytosolic sensors like AIM2 and NLR4 can also activate inflammasomes in response to fungal pathogens. These inflammasomes could have a role in the observed residual CASP1 activation by engaging different PANoptosome complexes. Further research with double or triple knock-out cells lacking ZBP1, AIM2, NLRP3, and/or NLR4 may address this disparity in inflammasome activation and PANoptotic cell death. RIPK1 and ZBP1 are reported to

assemble PANoptosome complex in response to TAK1 inactivation and IAV infection, respectively (17, 25–28). Future studies should address whether the RIPK1 PANoptosome complex is responsible for the residual inflammasome activation seen in the absence of ZBP1 during fungal *C. albicans* or *A. fumigatus* infection.

ZBP1 structurally is composed of two $Z\alpha$ domains in the N terminus followed by RHIM domains and a functionally uncharacterized C terminus region. RHIM domains mediate interactions with other RHIM domain-containing proteins and are crucial for regulation of cell death and inflammation. The $Z\alpha 2$ domain is critical in sensing nucleic acids, and we observed a critical role of the $Z\alpha 2$ domain in *C. albicans* or *A. fumigatus* infection to induce PANoptosis and inflammasome activation. It would be interesting to see what functions the $Z\alpha 1$ and RHIM domains and the C terminus region of ZBP1 have under these conditions.

Overall, our study highlights the critical role of the ZBP1-PANoptosome in driving PANoptosis and inflammation during fungal *C. albicans* or *A. fumigatus* infection. These findings improve our understanding of the host response to fungal pathogens and provide new directions for the development of targeted therapeutics for patients with mycosis, emphasizing the potential for therapeutic modulation of the PANoptosome in infectious and inflammatory diseases.

Experimental Procedures

Mice

All mice used in the current study were bred at the Animal Resource Center at St. Jude Children's Research Hospital and backcrossed to the C57BL/6 background for at least 10 generations. Animal studies were conducted under protocols approved by the St. Jude Children's Research Hospital Committee on the Use and Care of Animals. WT, *Zbp1*^{-/-} (21, 41), *Zbp1* ^{$\Delta Z\alpha 2/\Delta Z\alpha 2$} (20), *Casp1/11*^{-/-} (42), *Gsdmd*^{-/-} (43), *Asc*^{-/-} (44), *Mkl*^{-/-} (45), *Ripk3*^{-/-} (46), *Ripk3*^{-/-}*Casp8*^{-/-} (47), and *Casp1/11*^{-/-}*Ripk3*^{-/-}*Casp8*^{-/-} (18) mice have been described previously.

Bone marrow-derived macrophages (BMDMs) and human peripheral blood mononuclear cells (hPBMCs)

Primary granulocyte-macrophage colony-stimulating factor (GM-CSF)-derived BMDMs were cultivated for 7 days in RPMI (Cellgro, Corning, 10-040-CV) supplemented with 10% FBS (Biowest, S1620), 1% sodium pyruvate, 1% nonessential amino acids (Thermo Fisher Scientific, 11140-050), 1% penicillin and streptomycin (Thermo Fisher Scientific, 15070-063), 0.1% β -mercaptoethanol and 20 ng/ml of granulocyte-macrophage colony-stimulating factor (11). These BMDMs were then seeded into 12-well culture plates (3513, Costar) in DMEM (11995-065, Gibco) supplemented with 10% FBS and 1% penicillin and streptomycin. Primary hPBMCs derived from healthy donors were cultured in RPMI supplemented with 10% FBS and were seeded into 12-well culture plates at 1×10^6 cells/well.

Fungal culture

Malt-agar slants (2% (w/v)) were used to grow *A. fumigatus* A1160 strain. After 1 week of culture, *Aspergillus* conidia were harvested using water containing 0.1% (v/v) tween-20 (9), counted, and diluted to the desired MOI for infection. *C. albicans* (ATCC-SC5314) was grown in sebouraud dextrose (SBD) broth overnight at 28 °C in a shaking water bath. Before infection, *Candida* cultures were washed twice in $1 \times$ DPBS and enumerated using a Neubauer chamber.

Cell stimulation/infection

For *C. albicans* or *A. fumigatus* infection, primary BMDMs were infected in DMEM supplemented with 10% FBS and 1% penicillin and streptomycin at a MOI of 1 and 5, respectively, unless otherwise specified for indicated time periods. For *C. albicans* infection, hPBMCs were infected in RPMI supplemented with 10% FBS and 1% penicillin and streptomycin at a MOI of 1 or 2.

Immunoblot analysis

For caspase blots, primary BMDMs were lysed along with the supernatant using 50 μ l caspase lysis buffer (containing $1 \times$ protease inhibitors, $1 \times$ phosphatase inhibitors, 10% NP-40 and 25 mM DTT) and 100 μ l $4 \times$ SDS loading buffer. For signaling blots, supernatants were removed and BMDMs were washed one time with PBS at the indicated time points, followed by cell lysis with RIPA buffer. SDS-PAGE electrophoresis was carried out to separate proteins on 8%–12% polyacrylamide gels. PVDF membranes were used to transfer the resolved proteins, and the blots were blocked with 5% skim milk for 1 h at room temperature. Blots were incubated with primary antibodies at 4 °C, overnight, followed by incubation with secondary HRP antibodies for 1 h at room temperature. The GE Amersham Biosciences Imager 600 was used to image the immunoblots.

The following antibodies were used: anti-caspase-1 (AdipoGen, AG-20B-0042, 1:2000), anti-caspase-3 (Cell Signaling Technologies [CST], #9662, 1:1000), anti-cleaved caspase-3 (CST, #9661, 1:1000), anti-caspase-7 (CST, #9492, 1:1000), anti-cleaved caspase-7 (CST, #9491, 1:1000), anti-caspase-8 (CST, #4927, 1:1000), anti-cleaved caspase-8 (CST, #8592, 1:1000), anti-pMLKL (CST, #37333, 1:1000), anti-GSDMD (Abcam, ab209845, 1:1000), anti-ASC (AdipoGen, AG-25B-0006, 1:2000), anti-MLKL (Abgent, AP14272b, 1:1000), anti-RIPK3 (ProSci, #2283, 1:1000), anti-ZBP1 (Adipogen, AG-20B-0010, 1:1000), anti-GAPDH (CST, 5174, 1:5000), and HRP-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, anti-rabbit [111-035-047], 1:5000; anti-rat [112-095-003], 1:5000; and anti-mouse [315-035-047], 1:5000).

Real-time cell death analysis

Real-time cell death analysis was performed as previously described (17, 26). In brief, hPBMCs were seeded in 12-well plates (1×10^6 cells/well) and infected with *C. albicans*. Nuclei were stained using 20 nM SYTOX Green (Thermo Fisher Scientific, S7020). Images were analyzed using InCuCyte S3 software.

Fungal Infection Induces PANoptosis

IL-18 ELISA

Inflammatory cytokine IL-18 levels were assessed using the IL-18 ELISA kit from Invitrogen (BMS618-3) following the manufacturer's protocol.

Statistical analysis

Data analysis was performed using GraphPad Prism v8.0 software. Data are represented as mean \pm S.E. Statistical significance was determined by unpaired *t* test (two-tailed) with Welch's correction for two groups and 2-way ANOVA with Sidak's multiple comparisons test for three groups. The *P* values $p < 0.05$ were statistically significant.

Data availability

All data generated for this study are included within this manuscript.

Acknowledgments—We thank all the members of the Kanneganti laboratory for the scientific inputs, comments and suggestions and Rebecca Tweedell, PhD, for scientific editing and writing support. We thank V.M. Dixit and N. Kayagaki (Genentech) for the *Casp1*^{-/-} *Casp11*^{-/-} mutant mouse strain.

Author contributions—B. Banoth, R. K., and T.-D. K. conceptualization; B. Banoth, S. T., and R. K. data curation; B. Banoth, S. T., and R. K. formal analysis; B. Banoth, S. T., R. K., B. R. S., and B. Briard investigation; B. Banoth, S. T., and R. K. methodology; B. Banoth writing-original draft; B. Banoth, S. T., R. K., B. R. S., B. Briard, S. K., A. B., and T.-D. K. writing-review and editing; S. K. and A. B. resources; T.-D. K. supervision; T.-D. K. funding acquisition.

Funding and additional information—Work from our laboratory was supported by the US National Institutes of Health (AI101935, AI124346, AR056296, and CA253095 to T.-D. K.) and the American Lebanese Syrian Associated Charities (to T.-D. K.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: PAMPs, Pathogen-associated molecular patterns; DAMPs, damage-associated molecular patterns; PRRs, pattern recognition receptors; RIP, receptor interacting protein; RHIM, homotypic interaction motif.

References

1. Benedict, K., Richardson, M., Vallabhaneni, S., Jackson, B. R., and Chiller, T. (2017) Emerging issues, challenges, and changing epidemiology of fungal disease outbreaks. *Lancet Infect. Dis.* **17**, e403–e411 [CrossRef Medline](#)
2. Kullberg, B. J., and Arendrup, M. C. (2015) Invasive Candidiasis. *N. Engl. J. Med.* **373**, 1445–1456 [CrossRef Medline](#)
3. Segal, B. H. (2009) Aspergillosis. *N. Engl. J. Med.* **360**, 1870–1884 [CrossRef Medline](#)
4. Lionakis, M. S., Iliev, I. D., and Hohl, T. M. (2017) Immunity against fungi. *JCI Insight* **2**, [CrossRef](#)

5. Jorgensen, I., Rayamajhi, M., and Miao, E. A. (2017) Programmed cell death as a defence against infection. *Nat. Rev. Immunol.* **17**, 151–164 [CrossRef Medline](#)
6. Man, S. M., and Kanneganti, T. D. (2015) Regulation of inflammasome activation. *Immunol. Rev.* **265**, 6–21 [CrossRef Medline](#)
7. Karki, R., and Kanneganti, T. D. (2019) Diverging inflammasome signals in tumorigenesis and potential targeting. *Nat. Rev. Cancer* **19**, 197–214 [CrossRef Medline](#)
8. Man, S. M., and Kanneganti, T. D. (2015) Gasdermin D: the long-awaited executioner of pyroptosis. *Cell Res.* **25**, 1183–1184 [CrossRef Medline](#)
9. Briard, B., Karki, R., Malireddi, R. K. S., Bhattacharya, A., Place, D. E., Mavuluri, J., Peters, J. L., Vogel, P., Yamamoto, M., and Kanneganti, T. D. (2019) Fungal ligands released by innate immune effectors promote inflammasome activation during *Aspergillus fumigatus* infection. *Nat. Microbiol.* **4**, 316–327 [CrossRef Medline](#)
10. Karki, R., Man, S. M., Malireddi, R. K. S., Gurung, P., Vogel, P., Lamkanfi, M., and Kanneganti, T. D. (2015) Concerted activation of the AIM2 and NLRP3 inflammasomes orchestrates host protection against *Aspergillus* infection. *Cell Host Microbe* **17**, 357–368 [CrossRef Medline](#)
11. Lamkanfi, M., Malireddi, R. K., and Kanneganti, T. D. (2009) Fungal zymosan and mannan activate the cryopyrin inflammasome. *J. Biol. Chem.* **284**, 20574–20581 [CrossRef Medline](#)
12. Caffrey, A. K., and Obar, J. J. (2016) Alarmin(g) the innate immune system to invasive fungal infections. *Curr. Opin. Microbiol.* **32**, 135–143 [CrossRef Medline](#)
13. Kesavardhana, S., Malireddi, R. K. S., and Kanneganti, T. D. (2020) Caspases in Cell Death, Inflammation, and Pyroptosis. *Annu. Rev. Immunol.* **38**, 567–595 [CrossRef Medline](#)
14. Tummers, B., and Green, D. R. (2017) Caspase-8: regulating life and death. *Immunol. Rev.* **277**, 76–89 [CrossRef Medline](#)
15. Rogers, C., Erkes, D. A., Nardone, A., Aplin, A. E., Fernandes-Alnemri, T., and Alnemri, E. S. (2019) Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation. *Nat. Commun.* **10**, 1689 [CrossRef Medline](#)
16. Weinlich, R., Oberst, A., Beere, H. M., and Green, D. R. (2017) Necroptosis in development, inflammation and disease. *Nat. Rev. Mol. Cell Biol.* **18**, 127–136 [CrossRef Medline](#)
17. Christgen, S., Zheng, M., Kesavardhana, S., Karki, R., Malireddi, R. K. S., Banoth, B., Place, D. E., Briard, B., Sharma, B. R., Tuladhar, S., Samir, P., Burton, A., and Kanneganti, T. D. (2020) Identification of the PANoptosome: a molecular platform triggering pyroptosis, apoptosis, and necroptosis (PANoptosis). *Front. Cell Infect. Microbiol.* **10**, 237 [CrossRef Medline](#)
18. Gurung, P., Burton, A., and Kanneganti, T. D. (2016) NLRP3 inflammasome plays a redundant role with caspase 8 to promote IL-1 β -mediated osteomyelitis. *Proc. Natl. Acad. Sci. U S A* **113**, 4452–4457 [CrossRef Medline](#)
19. Karki, R., Sharma, B. R., Lee, E., Banoth, B., Malireddi, R. K. S., Samir, P., Tuladhar, S., Mummareddy, H., Burton, A. R., Vogel, P., and Kanneganti, T. D. (2020) Interferon regulatory factor 1 regulates PANoptosis to prevent colorectal cancer. *JCI Insight* **5**, [CrossRef](#)
20. Kesavardhana, S., Malireddi, R. K. S., Burton, A. R., Porter, S. N., Vogel, P., Pruett-Miller, S. M., and Kanneganti, T. D. (2020) The ZAlpha2 domain of ZBP1 is a molecular switch regulating influenza-induced PANoptosis and perinatal lethality during development. *J. Biol. Chem.* **295**, 8325–8330 [CrossRef Medline](#)
21. Kuriakose, T., Man, S. M., Malireddi, R. K., Karki, R., Kesavardhana, S., Place, D. E., Neale, G., Vogel, P., and Kanneganti, T. D. (2016) ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways. *Sci. Immunol.* **1**, aag2045 [CrossRef Medline](#)
22. Lamkanfi, M., Kanneganti, T. D., Van Damme, P., Vanden Berghe, T., Vanoverberghe, I., Vandekerckhove, J., Vandenabeele, P., Gevaert, K., and Nunez, G. (2008) Targeted peptide-centric proteomics reveals caspase-7 as a substrate of the caspase-1 inflammasomes. *Mol. Cell. Proteomics* **7**, 2350–2363 [CrossRef Medline](#)
23. Lukens, J. R., Gurung, P., Vogel, P., Johnson, G. R., Carter, R. A., McGoldrick, D. J., Bandi, S. R., Calabrese, C. R., Vande Walle, L., Lamkanfi, M.,

- and Kanneganti, T. D. (2014) Dietary modulation of the microbiome affects autoinflammatory disease. *Nature* **516**, 246–249 [CrossRef Medline](#)
24. Malireddi, R. K., Ippagunta, S., Lamkanfi, M., and Kanneganti, T. D. (2010) Cutting edge: proteolytic inactivation of poly(ADP-ribose) polymerase 1 by the Nlrp3 and Nlr4 inflammasomes. *J. Immunol.* **185**, 3127–3130 [CrossRef Medline](#)
 25. Malireddi, R. K. S., Gurung, P., Kesavardhana, S., Samir, P., Burton, A., Mummareddy, H., Vogel, P., Pelletier, S., Burgula, S., and Kanneganti, T. D. (2020) Innate immune priming in the absence of TAK1 drives RIPK1 kinase activity-independent pyroptosis, apoptosis, necroptosis, and inflammatory disease. *J. Exp. Med.* **217**, e20191644 [CrossRef Medline](#)
 26. Malireddi, R. K. S., Gurung, P., Mavuluri, J., Dasari, T. K., Klco, J. M., Chi, H., and Kanneganti, T. D. (2018) TAK1 restricts spontaneous NLRP3 activation and cell death to control myeloid proliferation. *J. Exp. Med.* **215**, 1023–1034 [CrossRef Medline](#)
 27. Malireddi, R. K. S., Kesavardhana, S., and Kanneganti, T. D. (2019) ZBP1 and TAK1: master regulators of NLRP3 inflammasome/pyroptosis, apoptosis, and necroptosis (PAN-optosis). *Front. Cell. Infect. Microbiol.* **9**, 406 [CrossRef](#)
 28. Samir, P., Malireddi, R. K. S., and Kanneganti, T. D. (2020) The PANoptosome: a deadly protein complex driving pyroptosis, apoptosis, and necroptosis (PANoptosis). *Front. Cell Infect. Microbiol.* **10**, 238 [CrossRef Medline](#)
 29. Zheng, M., Karki, R., Vogel, P., and Kanneganti, T. D. (2020) Caspase-6 is a key regulator of innate immunity, inflammasome activation, and host defense. *Cell* **181**, 674–687.e13 [CrossRef Medline](#)
 30. Zheng, M., Williams, E. P., Malireddi, R. K. S., Karki, R., Banoth, B., Burton, A., Webby, R., Channappanavar, R., Jonsson, C. B., and Kanneganti, T. D. (2020) Impaired NLRP3 inflammasome activation/pyroptosis leads to robust inflammatory cell death via caspase-8/RIPK3 during coronavirus infection. *J. Biol. Chem.* **295**, 14040–14052
 31. Sun, L., Wang, H., Wang, Z., He, S., Chen, S., Liao, D., Wang, L., Yan, J., Liu, W., Lei, X., and Wang, X. (2012) Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. *Cell* **148**, 213–227 [CrossRef Medline](#)
 32. Gurung, P., Anand, P. K., Malireddi, R. K., Vande Walle, L., Van Opdenbosch, N., Dillon, C. P., Weinlich, R., Green, D. R., Lamkanfi, M., and Kanneganti, T. D. (2014) FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes. *J. Immunol.* **192**, 1835–1846 [CrossRef Medline](#)
 33. Place, D. E., and Kanneganti, T. D. (2019) Cell death-mediated cytokine release and its therapeutic implications. *J. Exp. Med.* **216**, 1474–1486 [CrossRef Medline](#)
 34. Upton, J. W., Kaiser, W. J., and Mocarski, E. S. (2012) DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. *Cell Host Microbe* **11**, 290–297 [CrossRef Medline](#)
 35. Rebsamen, M., Heinz, L. X., Meylan, E., Michallet, M. C., Schroder, K., Hofmann, K., Vazquez, J., Benedict, C. A., and Tschopp, J. (2009) DAI/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to activate NF-kappaB. *EMBO Rep.* **10**, 916–922 [CrossRef Medline](#)
 36. Kesavardhana, S., Kuriakose, T., Guy, C. S., Samir, P., Malireddi, R. K. S., Mishra, A., and Kanneganti, T. D. (2017) ZBP1/DAI ubiquitination and sensing of influenza vRNPs activate programmed cell death. *J. Exp. Med.* **214**, 2217–2229 [CrossRef Medline](#)
 37. Zheng, M., and Kanneganti, T. D. (2020) The regulation of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis). *Immunol. Rev.* **297**, 26–38 [CrossRef](#)
 38. Jiao, H., Wachsmuth, L., Kumari, S., Schwarzer, R., Lin, J., Eren, R. O., Fisher, A., Lane, R., Young, G. R., Kassiotis, G., Kaiser, W. J., and Pasparakis, M. (2020) Z-nucleic-acid sensing triggers ZBP1-dependent necroptosis and inflammation. *Nature* **580**, 391–395 [CrossRef Medline](#)
 39. Lawlor, K. E., Khan, N., Mildenhall, A., Gerlic, M., Croker, B. A., D'Cruz, A. A., Hall, C., Kaur Spall, S., Anderton, H., Masters, S. L., Rashidi, M., Wicks, I. P., Alexander, W. S., Mitsuchi, Y., Benetatos, C. A., *et al.* (2015) RIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKL. *Nat. Commun.* **6**, 6282 [CrossRef Medline](#)
 40. Newton, K. K. E., Wickliffe, A., Maltzman, D. L., Dugger, A., Strasser, V. C., Pham, J. R., Lill, M., Roose-Girma, S., Warming, M., Solon, H., Ngu, J. D., Webster, V. M., and Dixit, V. M. (2016) RIPK1 inhibits ZBP1-driven necroptosis during development. *Nature* **540**, 129–133 [CrossRef Medline](#)
 41. Ishii, K. J., Kawagoe, T., Koyama, S., Matsui, K., Kumar, H., Kawai, T., Uematsu, S., Takeuchi, O., Takeshita, F., Coban, C., and Akira, S. (2008) TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. *Nature* **451**, 725–729 [CrossRef Medline](#)
 42. Kayagaki, N., Warming, S., Lamkanfi, M., Vande Walle, L., Louie, S., Dong, J., Newton, K., Qu, Y., Liu, J., Heldens, S., Zhang, J., Lee, W. P., Roose-Girma, M., and Dixit, V. M. (2011) Non-canonical inflammasome activation targets caspase-11. *Nature* **479**, 117–121 [CrossRef Medline](#)
 43. Karki, R., Lee, E., Place, D., Samir, P., Mavuluri, J., Sharma, B. R., Balakrishnan, A., Malireddi, R. K. S., Geiger, R., Zhu, Q., Neale, G., and Kanneganti, T. D. (2018) IRF8 regulates transcription of naips for NLRC4 inflammasome activation. *Cell* **173**, 920–933.e13 [CrossRef Medline](#)
 44. Ozoren, N., Masumoto, J., Franchi, L., Kanneganti, T. D., Body-Malapel, M., Erturk, I., Jagirdar, R., Zhu, L., Inohara, N., Bertin, J., Coyle, A., Grant, E. P., and Nunez, G. (2006) Distinct roles of TLR2 and the adaptor ASC in IL-1beta/IL-18 secretion in response to *Listeria monocytogenes*. *J. Immunol.* **176**, 4337–4342 [CrossRef Medline](#)
 45. Murphy, J. M., Czabotar, P. E., Hildebrand, J. M., Lucet, I. S., Zhang, J. G., Alvarez-Diaz, S., Lewis, R., Lalaoui, N., Metcalf, D., Webb, A. I., Young, S. N., Varghese, L. N., Tannahill, G. M., Hatchell, E. C., Majewski, I. J., *et al.* (2013) The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. *Immunity* **39**, 443–453 [CrossRef Medline](#)
 46. Newton, K., Sun, X., and Dixit, V. M. (2004) Kinase RIP3 is dispensable for normal NF-kappa B signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. *Mol. Cell Biol.* **24**, 1464–1469 [CrossRef Medline](#)
 47. Oberst, A., Dillon, C. P., Weinlich, R., McCormick, L. L., Fitzgerald, P., Pop, C., Hakem, R., Salvesen, G. S., and Green, D. R. (2011) Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. *Nature* **471**, 363–367 [CrossRef Medline](#)